Week in Review: Korea's Hanmi Signs $4.2 Billion Deal with Sanofi

Hanmi Pharma of Korea out-licensed global rights for three long-acting diabetes drugs to Sanofi in a blockbuster deal worth $4.2 billion; Sinocare, a Changsha glucose sensing device maker, will pay $273 million to acquire US-based Nipro Diagnostics, also in diabetes products; Roche will invest $136 million to build an Innovation Center in Shanghai; Bloomage BioTechnology, a China maker of aesthetic drug products, announced an $85 million investment from GIC of Singapore; ACEA Biosciences of San Diego and Hangzhou closed a $30 million venture capital round; Tianjin CanSino Biotech raised $30 million in venture capital to advance its vaccine programs; Tarrex Biopharma, a drug discovery startup based in Xiamen, purchased a 33% stake in Aranda Pharma of Finland and will co-develop its prostate cancer drug; iCarbonX of Shenzhen unveiled its big data/AI program to improve human health; Tsinghua University also announced a Medical Big Data Center at its Center for Statistical Science; JHL Biotech, a Taiwan-China biopharma, built a biologics CMO facility in Wuhan in just 11 days, using GE modular components; and Akers Biosciences of the US received CFDA approval of its diagnostic test for allergic reactions to heparin. More details.... Stock Symbols: (KSE: 128940) (NYSE: SNY) (SHZ: 300298) (SIX: RO, ROG) (HK: 963) (NSDQ: AKER; AIM:AKR.L) Share this with colleagues: // //